Antitumor Mechanisms and Clinical Applications of Shenqi Fuzheng Injection in Digestive System Cancers
Research Article
Open Access
CC BY

Antitumor Mechanisms and Clinical Applications of Shenqi Fuzheng Injection in Digestive System Cancers

Jinyuan Li 1*
1 Shenyang Pharmaceutical University
*Corresponding author: lij527123@gmail.com
Published on 26 November 2025
Volume Cover
TNS Vol.152
ISSN (Print): 2753-8826
ISSN (Online): 2753-8818
ISBN (Print): 978-1-80590-565-3
ISBN (Online): 978-1-80590-566-0
Download Cover

Abstract

Shenqi Fuzheng Injection (SFI) is a typical single compound from traditional Chinese medicine with a huge potential of SFI is mostly polysaccharide extracts of the substances of astragalus and Codonopsis, and the major three active components of SFI are astragalus polysaccharides, astragalosides and flavonoids. Molecular mechanisms of SFI have been extensively elucidated in gastric cancer, liver cancer, and other digestive system tumors based on recent basic and clinical studies. SFI interacts with multiple molecular pathways and molecular targets to achieve its therapeutic effects. The most prominent one is immune regulation, which is evidenced by the increased production of cytokines and chemokines and the alleviation of chemotherapy-induced immunosuppression. In the adjuvant treatment of digestive system cancers, SFI shows remarkable immunoregulatory and antitumor activities. Combining the SFI with immune checkpoint inhibitors and targeted therapies can be further explored to achieve synergistic antitumor effects based on the potential therapy effects of SFI. This review article summarizes the antitumor mechanisms of Shenqi Fuzheng Injection in digestive system cancers that are currently known, intending to help clinical use and future research directions.

Keywords:

Shenqi Fuzheng Injection, digestive system malignancies, immunoregulation, clinical application

View PDF
Li,J. (2025). Antitumor Mechanisms and Clinical Applications of Shenqi Fuzheng Injection in Digestive System Cancers. Theoretical and Natural Science,152,61-65.

References

[1]. Sung, H., et al. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Ca-a Cancer Journal for Clinicians, 71(3): p. 209-249.

[2]. Chen, G., & Huang, W. (2008). Research progress on chemical constituents and pharmacological effects of Astragalus. Chinese Journal of New Drugs, (17), 1482–1485.

[3]. Zhang, L., et al. (2020). A review on major active components of Codonopsis from different origins. Gansu Agricultural Science and Technology, (12), 65–69.

[4]. Zhao, X., et al. (2024). Research progress on the antitumor effects of Codonopsis and its active components. Chinese Journal of Traditional Chinese Medicine, 30(3), 121–125, 155.

[5]. Li, Y. (2017). Research progress on the active components and mechanisms of Astragalus in antitumor effects.

[6]. Zhou, D., et al. (2021). Antitumor mechanisms and clinical applications of Shenqi Fuzheng injection. Life Chemistry, 41(12), 2654–2661.

[7]. Wang, C., Li, Y., & Fang, F. (2022). Effect of Shenqi Fuzheng injection on leukopenia and T-cell subsets in patients with non-small cell lung cancer undergoing radiotherapy. Evidence-Based Complementary and Alternative Medicine, 2022, 2832739.

[8]. Lu, Y., & Lu, Y. X. (2006). Pharmacological effects and clinical applications of Shenqi Fuzheng injection. Shizhen Guoyi Guoyao, (10), 2083–2085.

[9]. Zhu, J., & Zhu, Y. (2014). Study on the mechanisms of Astragalus in preventing precancerous lesions of cervical cancer. Chinese General Practice, 17(13), 1562–1564.

[10]. Wei, X., & Zhang, R. (2024). Clinical efficacy and safety of Shenqi Fuzheng injection combined with chemotherapy in the treatment of gastric cancer. Chinese and Foreign Medical Treatment, 43(33), 175–178.

[11]. Li, X., et al. (2022). Effects of Shenqi Fuzheng injection combined with chemotherapy on chemosensitivity and T-lymphocyte subsets in patients with advanced gastric cancer. Journal of PLA Medicine, 34(7), 44–48.

[12]. Zhang, W., et al. (2009). Effects of Shenqi Fuzheng injection on T-lymphocyte subsets after TACE in patients with primary liver cancer. Medical Herald, 28(2), 213–214.

[13]. Di, L., Liu, R., & Yang, H. (2004). Clinical study of Shenqi Fuzheng injection for treatment of transcatheter arterial chemoembolization syndrome in primary liver cancer. Modern Oncology Medicine, (5), 473–474.

[14]. Bao, W., et al. (2017). Current status of research on Shenqi Fuzheng injection for digestive system tumors. Journal of Jinzhou Medical University, 38(2), 107–109.

[15]. Zhang, X., & Hou, X. (2021). Effects of Shenqi Fuzheng injection combined with XELOX chemotherapy on T-lymphocyte subsets, CEA, CA125, CA724, and quality of life in elderly patients with colorectal cancer. Chinese Journal of Gerontology, 41(23), 5201–5203.

References

[1]. Sung, H., et al. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Ca-a Cancer Journal for Clinicians, 71(3): p. 209-249.

[2]. Chen, G., & Huang, W. (2008). Research progress on chemical constituents and pharmacological effects of Astragalus. Chinese Journal of New Drugs, (17), 1482–1485.

[3]. Zhang, L., et al. (2020). A review on major active components of Codonopsis from different origins. Gansu Agricultural Science and Technology, (12), 65–69.

[4]. Zhao, X., et al. (2024). Research progress on the antitumor effects of Codonopsis and its active components. Chinese Journal of Traditional Chinese Medicine, 30(3), 121–125, 155.

[5]. Li, Y. (2017). Research progress on the active components and mechanisms of Astragalus in antitumor effects.

[6]. Zhou, D., et al. (2021). Antitumor mechanisms and clinical applications of Shenqi Fuzheng injection. Life Chemistry, 41(12), 2654–2661.

[7]. Wang, C., Li, Y., & Fang, F. (2022). Effect of Shenqi Fuzheng injection on leukopenia and T-cell subsets in patients with non-small cell lung cancer undergoing radiotherapy. Evidence-Based Complementary and Alternative Medicine, 2022, 2832739.

[8]. Lu, Y., & Lu, Y. X. (2006). Pharmacological effects and clinical applications of Shenqi Fuzheng injection. Shizhen Guoyi Guoyao, (10), 2083–2085.

[9]. Zhu, J., & Zhu, Y. (2014). Study on the mechanisms of Astragalus in preventing precancerous lesions of cervical cancer. Chinese General Practice, 17(13), 1562–1564.

[10]. Wei, X., & Zhang, R. (2024). Clinical efficacy and safety of Shenqi Fuzheng injection combined with chemotherapy in the treatment of gastric cancer. Chinese and Foreign Medical Treatment, 43(33), 175–178.

[11]. Li, X., et al. (2022). Effects of Shenqi Fuzheng injection combined with chemotherapy on chemosensitivity and T-lymphocyte subsets in patients with advanced gastric cancer. Journal of PLA Medicine, 34(7), 44–48.

[12]. Zhang, W., et al. (2009). Effects of Shenqi Fuzheng injection on T-lymphocyte subsets after TACE in patients with primary liver cancer. Medical Herald, 28(2), 213–214.

[13]. Di, L., Liu, R., & Yang, H. (2004). Clinical study of Shenqi Fuzheng injection for treatment of transcatheter arterial chemoembolization syndrome in primary liver cancer. Modern Oncology Medicine, (5), 473–474.

[14]. Bao, W., et al. (2017). Current status of research on Shenqi Fuzheng injection for digestive system tumors. Journal of Jinzhou Medical University, 38(2), 107–109.

[15]. Zhang, X., & Hou, X. (2021). Effects of Shenqi Fuzheng injection combined with XELOX chemotherapy on T-lymphocyte subsets, CEA, CA125, CA724, and quality of life in elderly patients with colorectal cancer. Chinese Journal of Gerontology, 41(23), 5201–5203.

Cite this article

Li,J. (2025). Antitumor Mechanisms and Clinical Applications of Shenqi Fuzheng Injection in Digestive System Cancers. Theoretical and Natural Science,152,61-65.

Data availability

The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.

About volume

Volume title: Proceedings of ICMMGH 2026 Symposium: Biomedical Imaging and AI Applications in Neurorehabilitation

ISBN: 978-1-80590-565-3(Print) / 978-1-80590-566-0(Online)
Editor: Sheiladevi Sukumaran, Alan Wang
Conference website: https://www.icmmgh.org/auckland.html
Conference date: 14 November 2025
Series: Theoretical and Natural Science
Volume number: Vol.152
ISSN: 2753-8818(Print) / 2753-8826(Online)

© 2024 by the author(s). Licensee EWA Publishing, Oxford, UK. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license. Authors who publish this series agree to the following terms:

1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this series.

2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this series.

3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See Open access policy for details).

For authors
For editors
For reviewers

Cookies are used by this site.
Copyright © 2024 EWA Publishing, its licensors, and contributors. All rights reserved, including text and data mining, AI training, and similar technologies.